Thymosin Beta-4 Peptide Reduces Heart Scarring After Heart Attack by Regulating the ROCK1 Protein | Research

The takeaway

Thymosin beta-4 reduces harmful cardiac scarring after heart attack by modulating the ROCK1 protein and may prevent the transformation of fibroblasts into scar-forming myofibroblasts in the damaged heart.

TB4 inhibits fibroblast-to-myofibroblast transformation
Myofibroblasts are the primary scar-producing cells after heart attack — blocking their formation could prevent the stiff scarring that leads to heart failure

What the researchers found

Following coronary ligation in adult mice, systemic TB4 injection led to a significant increase in miR-139-5p expression in heart tissue. The researchers identified ROCK1 as a downstream target of this miRNA pathway. Using real-time PCR, Western blot, and immunostaining in both mouse hearts and human cardiac cells, they confirmed that TB4 modulates ROCK1 protein levels both in vivo and in vitro.

Additionally, TB4 appeared to reverse or inhibit the transformation of fibroblasts into myofibroblasts — the cells primarily responsible for pathological scarring in the heart. The downstream mechanisms by which TB4 acts through ROCK1 were found to be cell-type specific, suggesting nuanced regulatory effects across different cardiac cell populations.

Why it matters

Heart attacks affect millions of people annually, and the scar tissue that forms afterward is a leading cause of heart failure. Current treatments can open blocked arteries but cannot regenerate damaged heart muscle or prevent scarring. TB4's ability to reduce pathological scarring through a defined molecular mechanism (ROCK1 regulation) provides a concrete therapeutic target. Since ROCK1 inhibitors are already being studied for various cardiac conditions, TB4 may offer a peptide-based approach to achieve similar benefits.

How the study worked

Researchers performed permanent coronary artery ligation in adult mice to induce heart attacks, then administered TB4 via systemic injection. MiRNA profiling was conducted on heart tissue from TB4-treated and untreated mice to identify differentially expressed microRNAs. Target analysis identified ROCK1 as a candidate protein. Validation was performed using real-time PCR, Western blot, and immunostaining in both adult mouse hearts (in vivo) and human cardiac cells (in vitro) to confirm TB4's effect on ROCK1 expression and fibroblast-to-myofibroblast transformation.

What this study cannot tell us

The study was conducted in mouse models and human cell lines, not in human patients, so clinical translation is uncertain. The permanent coronary ligation model creates more severe damage than most human heart attacks (where reperfusion therapy is standard). The study identified an association between TB4 and ROCK1 modulation but the precise mechanism — whether direct or indirect — remains to be fully elucidated. Sample sizes for the animal experiments were not specified in the abstract.

How to read the evidence

This is a preclinical study combining in vivo mouse experiments with in vitro human cell work. The multi-method validation (miRNA profiling, PCR, Western blot, immunostaining) strengthens the mechanistic findings, but the absence of human clinical data limits the evidence grade.

When this study was published

Published in 2025, this is a very recent study reflecting current understanding of TB4's molecular mechanisms in cardiac repair.

The bigger picture

Thymosin beta-4 has been studied for cardiac repair since landmark work showed it could reactivate progenitor cells and promote coronary vessel regrowth after heart attack. This study advances the mechanistic understanding by identifying a specific molecular pathway — the miR-139-5p/ROCK1 axis — through which TB4 reduces fibrosis. ROCK inhibitors (like fasudil) are already in clinical use for other conditions, so demonstrating that TB4 acts as a natural ROCK1 modulator bridges peptide biology and small-molecule pharmacology, potentially opening combination therapy approaches for post-infarction cardiac repair.

Questions still open

Can TB4 administration reduce cardiac fibrosis in human patients when given after a heart attack, and at what dose and timing?
Is the miR-139-5p/ROCK1 pathway the primary mechanism through which TB4 reduces scarring, or are there additional parallel pathways?
Could TB4 be combined with existing ROCK inhibitors for enhanced anti-fibrotic effects in the heart?

Common questions

What is thymosin beta-4 and what does it do in the body?

Thymosin beta-4 (TB4) is a small, naturally occurring peptide found throughout the body. It plays roles in wound healing, cell migration, and tissue repair. In the heart, it has been shown to promote blood vessel regrowth, activate cardiac progenitor cells, and — as this study demonstrates — reduce the formation of scar tissue after a heart attack by regulating proteins involved in fibrosis.

What is ROCK1 and why does it matter for heart health?

ROCK1 (Rho-associated coiled-coil containing protein kinase 1) is a protein involved in cell contraction, migration, and tissue remodeling. When overactive after a heart attack, it promotes fibrosis — the excessive scarring that makes the heart stiff and unable to pump efficiently. This study found that TB4 can modulate ROCK1 levels, potentially preventing this harmful scarring process.

Read the original research

Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals.

International journal of molecular sciences, 26(9)

View on PubMed ↗Publisher’s paper ↗

Citation

Maar, Klaudia; Thatcher, Jeffrey E; Karpov, Egor; Rendeki, Szilard; Gallyas, Ferenc; Bock-Marquette, Ildiko. (2025). Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals.. International journal of molecular sciences, 26(9). https://doi.org/10.3390/ijms26094131